Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H (1858) AI Stock Analysis

• Market Cap: HK$9.01B
• Dividend Yield: 1.85%
• Average Volume (3M): 1.20M
• Price to Earnings (P/E): 21.3
• Beta (1Y): 1.22
• Revenue Growth: 14.56%
• EPS Growth: 61.60%
• Country: HK
• Employees: 1,237
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.22
• Shares Outstanding: 95,140,500
• 10 Day Avg. Volume: 978,626
• 30 Day Avg. Volume: 1,198,522
• PEG Ratio: -0.45
• Price to Book (P/B): 1.08
• Price to Sales (P/S): 3.77
• P/FCF Ratio: -59.48
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: HK$17.50 ▲(13.78% Upside)

The overall stock score is primarily influenced by financial performance challenges, including declining revenue and negative cash flow. Technical analysis indicates weak momentum, while valuation metrics suggest moderate pricing. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Balance Sheet Stability

Minimal leverage indicates low financial risk, providing stability and flexibility to invest in growth opportunities.

Gross Profit Margin

High gross margins reflect efficient cost management, supporting profitability even amid revenue challenges.

Product Innovation

Commitment to innovation in medical devices can drive long-term growth and competitive advantage in the healthcare sector.

Negative Factors

Revenue Decline

A sharp decline in revenue suggests challenges in market demand or competitive pressures, impacting long-term growth prospects.

Negative Cash Flow

Negative cash flow from operations indicates potential liquidity issues, which can constrain the company's ability to invest in growth.

Profitability Margins

Decreasing profitability margins suggest operational inefficiencies or increased costs, which may hinder long-term financial performance.

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Beijing Chunlizhengda Medical Instruments Co., Ltd., an orthopedic medical device company, engages in the research and development, production, and sale of surgical implants, instruments, and related products in the People's Republic of China. It offers implantable orthopedic medical devices, which consist of joint prosthesis products and spinal products. The company primarily sells its products through distributors, or on ODM and OEM bases under the Chunli brand, as well as to hospitals directly. It also exports its products to various countries. The company was incorporated in 1998 and is headquartered in Beijing, China.

How the Company Makes Money

The company's revenue model primarily revolves around the sale of medical instruments and devices to hospitals, clinics, and healthcare providers both domestically and internationally. Key revenue streams include direct sales of orthopedic implants, surgical instruments, and rehabilitation equipment. Additionally, the company may generate income through partnerships with healthcare institutions for product development and distribution. Significant factors contributing to its earnings include a strong reputation for quality, compliance with medical regulations, and ongoing research and development efforts to innovate and expand its product line.

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Financial Statement Overview

Summary

The company shows strong balance sheet stability with minimal debt levels, but faces challenges with declining revenue and profitability margins. Negative cash flow from operations indicates potential financial stress, necessitating improvements in revenue generation and operational cash flows.

Income Statement

The gross profit margin remains strong at 64.08% in 2024, indicating efficient cost management in production. However, revenue showed a significant decline of 33.33% from 2023 to 2024, indicating challenges in maintaining sales volumes. The net profit margin also decreased, reflecting reduced profitability. EBIT and EBITDA margins have also decreased, suggesting pressures on operational efficiency.

Balance Sheet

The company maintains a solid equity position with a debt-to-equity ratio of 0.0003, indicating minimal leverage and financial risk. The equity ratio is robust at 81.38%, showcasing strong financial stability. Despite a slight drop in stockholders' equity, the company's balance sheet remains strong.

Cash Flow

The operating cash flow turned negative in 2024, indicating issues in cash generation from core operations. Free cash flow has also declined, pointing to challenges in maintaining liquidity. The free cash flow to net income ratio is negative, highlighting the need for cash management improvements.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	913.32M	805.86M	1.21B	1.20B	1.11B	937.69M
Gross Profit	550.05M	516.49M	875.89M	913.53M	854.54M	680.76M
EBITDA	178.05M	169.32M	340.65M	366.96M	360.99M	349.78M
Net Income	160.43M	124.99M	277.82M	307.72M	322.36M	283.37M
Balance Sheet
Total Assets	3.49B	3.47B	3.65B	3.41B	3.00B	1.54B
Cash, Cash Equivalents and Short-Term Investments	2.00B	1.89B	2.10B	1.72B	1.74B	690.12M
Total Debt	252.57K	866.44K	1.75M	1.31M	1.23M	1.85M
Total Liabilities	579.70M	644.39M	770.33M	690.07M	530.58M	460.41M
Stockholders Equity	2.91B	2.82B	2.88B	2.72B	2.47B	1.08B
Cash Flow
Free Cash Flow	151.20M	-51.07M	478.47M	16.10M	-34.62M	236.68M
Operating Cash Flow	208.64M	-1.90M	511.71M	41.01M	164.79M	260.68M
Investing Cash Flow	-165.47M	55.84M	-81.56M	-762.61M	―	-21.54M
Financing Cash Flow	-191.20M	-183.14M	-121.33M	―	1.07B	-11.88M

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 15.38
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1858, the sentiment is Negative. The current price of 15.38 is below the 20-day moving average (MA) of 16.50, below the 50-day MA of 16.80, and above the 200-day MA of 13.31, indicating a neutral trend. The MACD of -0.45 indicates Positive momentum. The RSI at 36.02 is Neutral, neither overbought nor oversold. The STOCH value of 10.31 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1858.

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1763	79 Outperform	HK$6.75B	14.73	8.59%	2.68%	13.59%	6.31%
1789	69 Neutral	HK$6.22B	19.41	11.24%	1.30%	25.18%	55.79%
2190	58 Neutral	HK$7.86B	44.51	4.99%	0.48%	35.01%	483.73%
1302	57 Neutral	HK$6.69B	87.08	1.98%	―	3.42%	-70.82%
1858	55 Neutral	HK$9.01B	21.30	8.69%	1.85%	14.56%	61.60%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
9996	39 Underperform	€4.15B	-16.94	-11.20%	―	29.25%	9.02%

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Corporate Events

Beijing Chunlizhengda Holds Successful Adjourned H Shareholders’ Meeting

Beijing Chunlizhengda Medical Instruments Co., Ltd. held an adjourned H Shareholders’ Class Meeting on December 3, 2025, in Beijing. The meeting, which was chaired by Ms. Shi Wenling, complied with PRC laws and Hong Kong Stock Exchange listing rules. All directors attended, with some participating via telephone. The meeting involved a registered poll for voting, with no restrictions or abstentions noted among shareholders.

Beijing Chunlizhengda Declares Third Quarter Dividend for 2025

Beijing Chunlizhengda Medical Instruments Co., Ltd. announced a cash dividend for the third quarter of 2025, with shareholders approving a dividend of RMB 2.1 per 10 shares. The dividend will be paid in Hong Kong dollars at an exchange rate of RMB 1 to HKD 1.09716, with a payment date set for January 19, 2026. The announcement also detailed withholding tax rates applicable to different categories of shareholders, impacting non-resident enterprises and individuals, as well as mainland investors through stock connect programs.

Beijing Chunlizhengda Medical Instruments Co., Ltd. Successfully Concludes EGM with All Resolutions Passed

Beijing Chunlizhengda Medical Instruments Co., Ltd. successfully held its Extraordinary General Meeting (EGM) and A Shareholders’ Class Meeting on November 19, 2025, in compliance with relevant laws and regulations. All proposed resolutions were passed without opposition, and the meetings were attended by all directors, either in person or by telephone, indicating strong governance and shareholder engagement.

Beijing Chunlizhengda Medical Instruments Reschedules H Shareholders’ Meeting

Beijing Chunlizhengda Medical Instruments Co., Ltd. announced the adjournment of its H Shareholders’ Class Meeting due to insufficient voting rights representation. The meeting, originally scheduled for November 19, 2025, will now be held on December 3, 2025. The company has ensured that previously submitted proxy forms remain valid for the rescheduled meeting, maintaining continuity for shareholders.

Beijing Chunlizhengda Invests in Structured Deposit Products

Beijing Chunlizhengda Medical Instruments Co., Ltd. has announced the subscription of structured deposit products with various branches of the Bank of Beijing and Shanghai Pudong Development Bank, amounting to significant investments using both internal resources and temporary idle proceeds from public issuance of A shares. These transactions, which exceed 5% but are below 25% of applicable percentage ratios, are classified as discloseable transactions under the Listing Rules, requiring reporting and announcement but exempt from shareholder approval.

Beijing Chunlizhengda Medical Instruments Announces Strategic Governance Changes

Beijing Chunlizhengda Medical Instruments Co., Ltd. has announced an extraordinary general meeting scheduled for November 19, 2025, to discuss significant changes in its governance structure. The meeting will consider the abolishment of the Supervisory Committee, amendments to the Articles of Association, and changes to the rules of procedures for general and board meetings. Additionally, amendments to the working system for independent directors and management measures for the use of proceeds will be reviewed, along with the 2025 Third Quarterly Profit Distribution Plan. These proposed changes indicate a strategic shift in the company’s governance and operational procedures, potentially impacting its stakeholders and market positioning.

Beijing Chunlizhengda Proposes Governance Changes at H Shareholders’ Meeting

Beijing Chunlizhengda Medical Instruments Co., Ltd. has announced a class meeting for its H shareholders to discuss and potentially approve significant changes, including the abolishment of the Supervisory Committee and amendments to the Articles of Association and procedural rules for meetings. These changes could streamline the company’s governance structure, potentially impacting its operational efficiency and strategic decision-making processes.

Beijing Chunlizhengda Proposes Governance Amendments Amid Regulatory Changes

Beijing Chunlizhengda Medical Instruments Co., Ltd. has announced proposed amendments to its Articles of Association and internal management policies to comply with recent changes in the Company Law of China and the Hong Kong Stock Exchange’s listing rules. Key changes include the abolishment of the supervisory committee, with its functions transferred to the audit committee, and alignment with the expanded paperless listing regime. These amendments, aimed at enhancing corporate governance and operational efficiency, are subject to shareholder approval at an upcoming extraordinary general meeting.

Beijing Chunlizhengda Announces Third Quarter 2025 Dividend

Beijing Chunlizhengda Medical Instruments Co., Ltd. has announced a cash dividend for the third quarter of 2025, declaring RMB 2.1 per 10 shares. The dividend, subject to shareholder approval on November 19, 2025, will be paid on January 19, 2026, with specific withholding tax rates applied to different categories of shareholders. This announcement reflects the company’s commitment to providing returns to its investors and may influence its market positioning by attracting more stakeholders.

Beijing Chunlizhengda Medical Instruments Releases Q3 2025 Financial Results

Beijing Chunlizhengda Medical Instruments Co., Ltd. has released its unaudited financial results for the third quarter of 2025, prepared according to Chinese Accounting Standards. The report highlights the company’s financial performance over the nine months ending September 30, 2025, and advises investors to be aware of potential investment risks. The report is available in both Chinese and English, with the Chinese version taking precedence in case of discrepancies.

Beijing Chunlizhengda Medical Instruments Schedules Board Meeting for Quarterly Results

Beijing Chunlizhengda Medical Instruments Co., Ltd. announced that its board of directors will meet on October 30, 2025, to approve the company’s third quarterly results for the nine months ending September 30, 2025. The meeting will also consider the payment of an interim dividend, which could impact the company’s financial strategy and shareholder returns.

Beijing Chunlizhengda Medical Instruments Schedules Board Meeting for Quarterly Results

Beijing Chunlizhengda Medical Instruments Co., Ltd. announced that its board of directors will meet on October 30, 2025, to approve the company’s third quarterly results for the nine months ending September 30, 2025. The meeting will also consider the payment of an interim dividend, which could impact the company’s financial strategy and shareholder returns.